Talha Qureshi
Tue, November 18, 2025 astatine 4:07 AM CST 2 min read
The ratings travel the company’s fiscal Q3 2025, released connected October 30, wherever the institution topped estimates. The gross grew 12.3% year-over-year to $110.33 million, surpassing estimates by $9.78 million. The EPS of $0.00 besides topped estimates by $0.07. Management attributed gross maturation to a 92% year-over-year maturation successful IBSRELA revenue, which reached $78.2 million, surpassing the company’s estimates by $7 million. Management noted that the outperformance of IBSRELA is driven by sustained request for a differentiated attraction enactment by IBS-C patients. Therefore, the institution raised IBSRELA guidance and expects 2025 gross to beryllium betwixt $270 cardinal and $275 million.
Bratzel from Piper Sandler noted the maturation successful IBSERLA proves the company’s income unit strength. However, the steadfast awaits ceremonial grounds of Xphozah’s near- and immediate-term outlook to formulate a much constructive sentiment connected Ardelyx, Inc. (NASDAQ:ARDX).
Ardelyx, Inc. (NASDAQ:ARDX) is simply a biopharmaceutical institution that develops and commercializes first-in-class medicines for gastrointestinal and kidney-related diseases.
While we admit the imaginable of ARDX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.

3 days ago
4






English (CA) ·
English (US) ·
Spanish (MX) ·